BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE
—Expands BioCryst portfolio of targeted oral prophylactic therapy options to meet patients’ individual needs and preferences—
—Expands BioCryst portfolio of targeted oral prophylactic therapy options to meet patients’ individual needs and preferences—